Posted by Michael Wonder on 18 Apr 2023
HUTCHMED announces NDA acceptance in China for fruquintinib in second-line gastric cancer
18 April 2023 - HUTCHMED today announces that its new drug application for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastro-esophageal junction adenocarcinoma in China has been accepted for review by the China National Medical Products Administration.
The new drug application is supported by data from the FRUTIGA study, a randomised, double-blind, Phase 3 study in China to evaluate fruquintinib combined with paclitaxel compared with paclitaxel monotherapy, for second-line treatment of advanced gastric cancer.
